What the current trial can answer ClinicalTrials.gov lists a recruiting phase 2 split-wound study of 0.1% topical GHK-Cu gel
The 5mL option spreads the peptide across a larger volume, making each unit on the syringe represent a smaller dose
Also, your healthcare provider may consider factors and evaluations before proceeding with the treatment
GLP-1-class drugs amplify this in one indirect way: they work largely by suppressing appetite, which can drive protein intake and overall calories very low if a person simply "isn't hungry." Under-eating protein while losing weight quickly is the single biggest driver of avoidable muscle loss
It functions as a dual GIP/GLP-1 receptor agonist, meaning one peptide chain binds to and activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor
A 2025 peer-reviewed reply in Pharmaceuticals by Jzwiak and colleagues explicitly flagged BPC-157s pro-angiogenic and nitric oxide-related activities as warranting serious investigation regarding neurodegenerative disease